

姓名	毕毅	籍贯	山东荣成	最后学历	研究生					
最后毕业院校	中国药科大学		所学专业		药物化学					
研究生导师类别	博士/硕士研究生导师		职称/职务		教授/科技处处长					
办公电话	0535-6902524		电子邮件		13361368686@163.com					
个人学习及工作经历	1998.9-2002.7 中国药科大学国家基础药学理科基地班，学士 2002.9-2007.7 中国药科大学药物化学直博研究生，博士 2015.9-2016.9 芝加哥大学普利兹克医学院，访问学者 2007.7-至今 烟台大学药学院药物化学教研室，讲师，副教授，教授，硕导，博导									
学术兼职	1. 《中国化学快报》青年编委 2. 山东省人民政府学位委员会药学专业学位研究生教育指导委员会委员									
目前研究方向简介	聚焦恶性肿瘤和炎症等领域，利用计算机辅助药物设计，从事天然产物来源的先导化合物的发现、结构优化、生物活性和机制探索研究方面的工作。									
近五年主持（或参与）教学、科研项目	1. Ocotillol 型 C-24 差向异构体分子探针化学构建及抗 MRSA 作用机制研究 (81773563)，国家自然科学基金面上项目 2.“肿瘤多药耐药逆转活性天然产物”山东省高等学校青创科技计划创新团队 (20202020KJM003) 3. 具有抗肿瘤活性的夫西地酸衍生物的设计合成与初步成药性研究 (2019GSF108177)，山东省重点研发计划项目									
近五年教学、科研获奖及专利	获奖： 2021 年山东省教育系统女职工建功立业标兵 2021 年山东省优秀研究生指导教师 2020 年山东省硕士研究生优秀论文指导教师 2019 年山东省教育系统优秀共产党员 2018 年山东省第八届高等教育教学成果奖一等奖，二等奖 2017 年第四届山东省高校青年教师教学比赛二等奖 授权专利： 1. 具有肿瘤耐药逆转活性的 α-常春藤皂苷元衍生物及其制备方法和用途，ZL201710065183.9 2. 一种 α-常春藤皂苷元衍生物及其制备方法和用途, ZL201610607760.8 3. 夫西地酸衍生物及其合成制备方法和应用，ZL 2018 1 0504437.7 4. 具有抗肿瘤活性的夫西地酸衍生物及其合成制备方法，ZL2018 1 1105318.0 5. 氨基取代的夫西地酸衍生物在制备抗真菌药物中的应用，ZL2018 1 1479612.8 6. 一类夫西地酸衍生物制备抗肿瘤药物的用途，ZL2018 1 1112283.3									

近五年已发表的 代表性论著	<p>1. Tao Yu, Hao-ran Cheng, Xiao-li Li, Wen-tao Huang, Hai-xia Li, Xiao-jin Gao, Jia-ning Zhao, Xin Zhang, Xiao-xiao Gu, Yi Bi*, Lei-ming Zhang*. Design and synthesis of hederagenin derivatives modulating STING/NF-κB signaling for the relief of acute liver injury in septic mice. <i>European Journal of Medicinal Chemistry</i>, 2022, 114911.</p> <p>2. Jun-jun Long, Tian-hao Ying, Lei Zhang, Tao Yu, Jin-hui Wu, Ya-sen Liu, Xiao-li Li, Guo-liang You, Lei-ming Zhang*, Yi Bi*. Discovery of fusidic acid derivatives as novel STING inhibitors for treatment of sepsis. <i>European Journal of Medicinal Chemistry</i>, 2022, 244, 114814.</p> <p>3. Ying-jie Wang, Dou-dou Zhang, Gong-shan Ma, Zong-yi Su, Ming-ming Liu, Rui Wang, Qing-guo Meng, Yi Bi*, Hong-bo Wang*. Design, synthesis, and biological evaluation of ocotillol derivatives fused with 2-aminothiazole via A-ring as modulators of P-glycoprotein-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i>, 2022, 243, 114784.</p> <p>4. Wentao Huang, Yingjie Wang, Si Xu, Hui Qiao, Haoran Cheng, Linxu Wang, Shuqi Liu, Qingjian Tian, Ruodong Wang, Hongbo Wang**, Yi Bi *.Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles. <i>European Journal of Medicinal Chemistry</i>, 2022, 232, 114207.</p> <p>5. Yucheng Cao, Kaiyi Wang, Jiali Wang, Haoran Cheng, Mengxin Ma, Qingguo Meng*, Xiaopeng Li, Yi Bi*. Design, synthesis, and antibacterial evaluation of ocotillol derivatives with polycyclic nitrogen-containing groups. <i>Future Medicinal Chemistry</i>, 2021, 13(12):1025-1039.</p> <p>6. Binghua Wang , Shuqi Liu , Wentao Huang, Mengxin Ma, Xiaoqian Chen, Wenxuan Zeng, Kaicheng Liang, Hongbo Wang*, Yi Bi*, Xiaopeng Li. Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity. <i>European Journal of Medicinal Chemistry</i>, 2021, 211, 103107.</p> <p>7. Yucheng Cao, Jingxuan , Wentao Ji, Kangle Shang, Kaicheng Liang, Jing Lu*, Yi Bi*, Xiaomin Luo. Synthesis, antifungal activity and potential mechanism of fusidic acid derivatives possessing amino-terminal groups. <i>Future Medicinal Chemistry</i>, 2020, 12(9), 763-774.</p> <p>8. Mengqi Guo, Qianwen Ren, Binghua Wang, Wentao Ji, Jingxuan Ni, Yaqi Feng, Yi Bi*, Jingwei Tian, Hongbo Wang*. Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i>, 2019, 182, 111668.</p> <p>9. Jing Lu*, Jing-Xuan Ni, Jin-An Wang, Ze-Yun Liu, Kang-Le Shang, Yi Bi*. Integration of multiscale molecular modeling approaches with the design and discovery of fusidic acid derivatives. <i>Future Medicinal Chemistry</i>, 2019, 11(12), 1427-1442.</p> <p>10. Jingxuan Ni, Mengqi Guo, Yucheng Cao, Lei Lei, Kangli Liu, BinghuaWang, Fangfang Lu, Rong Zha, Xiangwei Gao, Chunhong Yan, HongboWang*, Yi Bi*. Discovery, synthesis of novel fusidic acid derivatives possessed amino-terminal groups at the 3-hydroxyl position with anticancer activity. <i>European Journal of Medicinal Chemistry</i>, 2019, 162, 122-131.</p> <p>11. Xiao Wang, Qian-wen Ren, Xian-xuan Liu, Yan-ting Yang, Bing-huaWang, Rong Zha, Jia Grace Qi, Jing-wei Tian*, Hong-boWang*, Yi Bi*. Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents. <i>European Journal of Medicinal Chemistry</i>, 2019, 161, 364-377.</p> <p>12. Yanting Yang, Daokun Guan, Lei Lei, Jing Lu, Jia Qi Liu, Gangqiang Yang, Chunhong Yan, Rong Zhai, Jingwei Tian, Yi Bi*, Fenghua Fu, Hongbo Wang*. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. <i>Toxicology and Applied Pharmacology</i>, 2018, 341, 98-105.</p> <p>13. Xian-xuan Liu, Yan-ting Yang, Xiao Wang, Kai-yi Wang, Jia-qi Liu, Lei Lei, Xiao-min Luo, Rong Zhai , Feng-hua Fu, Hong-bo Wang*, Yi Bi*. Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity. <i>European Journal of Medicinal Chemistry</i>, 2017, 141, 427-439.</p>
指导研究生 情况	博士：已毕业 3 名，在读 1 名。 硕士：已毕业 13 名，在读 8 名。